IXICO PLC (AIM:IXI, FRA:PYPB, OTC:PHYOF), the AI-driven brain imaging specialist, said it has been awarded a new contract by an existing unnamed US biopharmaceutical client worth more than US$500,000 over 12 months.
The company will support a phase II Huntington’s disease (HD) trial, analysing MRI scans from 10 centres across the world.
Chief executive Giulio Cerroni said: "Huntington's disease is a devastating rare neurological condition with unmet medical needs.
“IXICO has worked on 16 HD clinical studies since 2007 and we are pleased to build further momentum in our mission to support our clients in identifying new insights into this challenging rare, neurodegenerative disease.
“Our technology services and AI data analytics enable clients to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression in support of much needed new drug development."